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ETHICAL RESPONSIBILITIES OF PATIENTS AND
CLINICAL GENETICISTS
ALLEN BUCHANAN, PH.D.*
I. NOT THE ETHics OF PUBLIC POLICY
Ethical issues concerning genetic testing arise in two areas: public
policy and individual conduct. Confusion results if these are not kept
distinct because factors that may be relevant for determining what is
acceptable public policy may not be relevant, or at least may not carry
as much weight for determining the ethical, as opposed to the legal,
responsibilities of individual patients and physicians. For example,
even if there are strong reasons for concluding that a pregnant wo-
man has an ethical obligation to undertake a genetic test that would
detect and allow for the correction of a serious defect in utero, it does
not follow that it would be ethically acceptable or prudent to sanction
this obligation with the force of law. Concerns that a legal obligation
might be enforced in a discriminatory way against poor women or ra-
cial minorities may argue against the imposition of a legal obligation.
Similarly, sound ethical analysis should recognize a distinction be-
tween types of public policy. Public policy includes not only the use of
criminal, tort, or regulatory law to mandate, prohibit, or increase the
costs of certain choices, but also extends to the provision of informa-
tion and the use of techniques of persuasion through the "social mar-
keting" of public health messages about the availability of genetic tests
and the options available to those who test positive. A conclusive rea-
son for not making it a legal duty for persons at risk to take a particu-
lar genetic test may not be a good reason against initiating a public
awareness campaign designed to encourage the same group to take
that test.
This essay focuses on the ethical responsibilities of individuals
who must decide whether to undergo a genetic test or who have al-
ready received the results of such a test and on the responsibilities of
* Professor, Department of Philosophy University of Arizona. I am grateful to Adele
Franks, M.D., Director of Scientific Research, Centers For Disease Control and Prevention,
Atlanta, Georgia, and to Karen Rothenberg, Marjorie Cook Professor of Law and Director,
Law and Health Care Program, University of Maryland, School of Law, for their astute
comments on an earlier draft of this paper.
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the clinicians who reveal the test results to them.' The analysis offered
here bears only indirectly, at best, on the ethics of public policy.
To state that the ethics of individual choice and the ethics of pub-
lic policy are distinct is not to state that they are unrelated. In some
cases, the existence of a particular public policy can shape the ethical
responsibilities of individuals. For example, if public policy provides
adequate health care for the elderly, then the ethical responsibilities
of children for their aged parents may be narrower, or at least differ-
ent in character, from what they would be in the absence of such poli-
cies. Similarly, public policy choices in the United States have
resulted in a situation in which some people are at risk for unin-
surability if they are known to have tested positive for a genetic condi-
tion,' a fact that may undercut what might otherwise be their
obligation to inform their relatives that they too are at risk.
II. INDIIDUALS' ETHICAL RESPONSIBILITIES: FIVE REASONS FOR A
FRESH ANALYSIS CONCERNING TESTING AND TELLING
There are five reasons why a critical examination of the ethical
responsibilities of individual patients and clinicians is necessary at this
time.
1. The Rapid Increase in the Number and Types of Genetic Tests
First, a deluge of genetic tests is on the way. Suppose that the
current repertoire of genetic tests is represented as a small stream of
water pouring over a precipice and the existing totality of medical ge-
neticists and genetic counselors as a single individual trying to catch
the stream in a small cup. Now suppose that what had been a small
stream becomes a huge waterfall - but that there is still only one
individual, with one small cup, vainly attempting to catch the torrent.
It has been reported that one company plans to market a test kit
whereby a single blood sample will be used to detect over 100 abnor-
mal genetic conditions.3 A clinic at a state university medical center is
already direct marketing a mail-in genetic test for hereditary
hemochromatosis,4 and a mail-in genetic test for cystic fibrosis5 has
1. I will use the term "clinician" to cover both physicians and genetic counselors.
2. See Paul R. Billings et al., Discrimination as a Consequence of Genetic Testing, 50 AM. J.
HUM. GENETICS 476, 478 (1992).
3. Electronic communication from Robert Cook-Deegan, Director of the National
Cancer Policy Board, Institute of Medicine and Commission on Life Sciences, National
Academy of Sciences (Oct. 1996).
4. Hereditary hemochromatosis is an autosomal recessive genetic disorder of exces-
sive iron storage that can cause tissue damage and dysfunction of the liver, pancreas, heart,
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already been marketed in the United Kingdom.6 In the coming de-
cades, there will be many more tests with more ethical choices for
more people, patients, and physicians.
2. The Need to Challenge the Reproductive-Choice Paradigm
Second, to a large extent, thinking about the ethical responsibili-
ties of patients and clinicians has been shaped - and, I will argue,
distorted - by the dominance of what I shall call "the reproductive-
choice paradigm."7 The reproductive-choice paradigm takes repro-
ductive-predictive genetic tests to be the paradigm of genetic tests.
Here "reproductive-predictive tests" means those genetic tests, such as
those for cystic fibrosis carrier status, that prospective parents some-
times undergo to gain information to guide their reproductive deci-
sions. Until very recently, by far the most common encounter
between a patient and a clinician in which issues of genetic testing
were broached focused on the question of whether to conceive or
whether to carry a fetus to term. The existing consensus on the ethi-
cal responsibilities of physicians was forged as a response to the dis-
tinctive features of situations in which patients face that question.
Among the most distinctive features of diagnostic-predictive tests are
that (1) they touch upon the most intimate of human relationships
for which the strongest case for privacy can be made; (2) the only
options for responding to a positive test have been to accept the risk
of a genetic disorder, to avoid conception, or to terminate the preg-
nancy, with the latter option raising one of the most divisive issues our
society has known - the question of morality of abortion; and (3) it is
in this area of reproductive choices that medical professionals are
most acutely aware of the need to dissociate themselves from the taint
of eugenics.8 All three of these facts lend support to the conclusion
and pituitary. See DORmAND'S MEDICAL DICTIONARY 747 (28th ed. 1994). A mail-in test ex-
ists to test for this genetic disorder and is offered by the Michigan State University DNA
Diagnostic Program.
5. Cystic fibrosis (CF) is a generalized, autosomal recessive disorder of infants, chil-
dren, and young adults, in which there is widespread dysfunction of the exocrine glands.
See DOL.AND'S MEDICAL DICTIONARY 628 (28th ed. 1994). CF is characterized by signs of
chronic pulmonary disease due to excess mucus production in the respiratory tract. See id.
6. See Science and Technology Committee, House of Commons, Human Genetics:
The Science and Its Consequences, VOL I, REP. AND MINUTES OF PROCEEDINGS, (3d Rep.
1994-95 session) [hereinafter SCIENCE AND TECHNOLOGY COMMITTEE].
7. See, e.g., Gail Geller et al., Incorporation of Genetics in Primary Care Practice. Will Physi-
cians Do the Counseling and Will They Be Directive?, ARCHIVES FAMILY MED. 1119 (1993).
8. Eugenics is defined as the "branch of science concerned with the study of the he-
reditary improvement of man by genetic control." MELLONI'S ILLUSTRATED MEDICAL DIC-
TIONARY 156 (2d ed. 1985); see generally DANIEL J. KEVLES, IN THE NAME OF EUGENICS:
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that physicians should avoid "imposing their own values" or the pre-
sumed values of society on patients in the reproductive-predictive test
encounter.
To a large extent, it is in this distinctive context - the context
that shapes the peculiar ethical significance of reproductive-predictive ge-
netic tests - that a conception of the ethical responsibilities of clini-
cians has developed. But it should not be assumed that ethical
principles for dealing with reproductive-predictive tests (such as amni-
ocentesis to detect Down Syndrome, or a carrier test for cystic fibrosis)
ought to be generalized to all genetic tests, including diagnostic-pre-
dictive tests (also called presymptomatic tests) for adult onset disor-
ders such as breast cancer, colon cancer, and hereditary
hemochromatosis. In particular, we should not assume that the same
norm of nondirectiveness9 that may be appropriate for reproductive-
predictive tests is also appropriate for diagnostic-predictive tests, and
we should not assume that considerations of privacy weigh as heavily.
Nor should we assume that all diagnostic-predictive tests are the same
from an ethical point of view.
3. The Ethical Responsibilities of Patients Regarding Genetic Testing
It is crucial to focus on the ethical responsibilities of patients be-
cause there appears to be nothing approaching a consensus on what
their ethical responsibilities are. The point is not that there are devel-
oped, but opposing, accounts of the ethical responsibilities of pa-
tients; rather, there is not a clear consensus that an account of the
ethical responsibilities of patients is needed.
Here, too, the history of genetic testing - the dominance of the
reproductive-choice paradigm - clouds the way we think about the
ethical issues. Acceptance of the norm of nondirectiveness by genetic
counselors, a norm which may be plausible for reproductive-predictive
tests at a certain stage of social history, has encouraged a failure to
develop an adequate conception of the ethical responsibilities of
patients.
When clinicians observe the norm of nondirectiveness, but fail to
make it clear that there is a distinction between what they as medical
professionals should do and what the patients should do, clinicians
may implicitly convey the message to patients that the choice con-
fronting them is simply a matter of "personal values" - that the idea
GENETICS, AND THE USES OF HuMAN HEREDITY (1995) (identifying the past negative associa-
tion of the word eugenics, after the second World War, with its connection to racism).
9. See infra text Section 1V.E.
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of ethical responsibility does not apply. But from the fact (if it is a
fact) that clinicians should not tell patients what their ethical responsi-
bilities are, it does not follow that patients have no ethical responsibili-
ties, and that whatever they do is acceptable as long as it reflects their
own values and is freely chosen. Ethical responsibilities, in general,
are not reducible to acting consistently on whatever values one hap-
pens to have. Authenticity is an element of morality, not the whole of
it. A person's action may be authentic in the sense that it is an expres-
sion of his deepest, stable values, yet it may be a wrongful action.
4. The Need to Challenge the Therapeutic Pessimism Paradigm
So far I have suggested that the fact that the formative context for
the development of assumptions about the ethical responsibilities of
patients and clinicians was the reproductive-predictive testing encoun-
ter encourages unfortunate generalizations to the ethics of diagnostic-
predictive tests. I now want to suggest that the history of diagnostic-
predictive tests, up to the present time, has the same tendency.
At present, with a few exceptions, diagnosis for genetic diseases
outstrips treatment.10 This is especially true for the genetic tests that
currently receive the most extensive media coverage and public dis-
cussion, including tests for the BRCA11 1 and BRCA2 12 genes, the APO
E4V3 Alzheimer's gene test, and the test for the Huntington's gene. In
each of these cases, the medical benefit of testing is very dubious at
present because there is no effective treatment for the condition. If
all genetic tests were like these, the ethical landscape of genetic test-
ing would be far simpler than it is in fact.
If we focus exclusively on tests for those late-onset conditions that
are lethal and for which there is no effective treatment, such as Hunt-
ington's disease and Alzheimer's disease, we are likely to persist in the
same ethical assumptions that developed in response to the reproduc-
tive-predictive test encounter. In particular, we will assume that
10. See TASK FORCE ON GENETIC TESTING, NIH-DOE WORKING GROUP ON ETHICAL,
LEGAL, AND SOCIAL IMPLICATIONS OF HUMAN GENOME RESEARCH, PROMOTING SAFE AND EF-
FEcTIVE GENETIC TESTING IN THE UNITED STATES 3 (1997).
11. BRCA1 is a gene believed to confer a greater than normal risk of breast cancer. See
Jeffrey P. Struewing et al., The Carier Frequency of the BRCA1 185deLAG Mutation is Approxi-
mately I Percent in Ashkenazi Jewish Individuals, 11 NATURE GENETICS 198, 199 (1995).
12. BRCA2 is a genetic mutation that is believed to confer a higher than normal risk of
breast cancer. See Karen H. Rothenberg, Breast Cancer, The Genetic "Quick Fix" and the Jewish
Community: Ethical, Legal, and Social Challenges, 7 HEALTH MATRIX 97, 101 n.24 (1997).
13. "The inheritance of apolipoprotein (APO) E4 allele is an important risk factor for
late-onset Alzheimer's disease." B. Permanne et al., Detection ofApolipoprotein E/dimeric Solu-
ble Amyloid Beta Complexes in Alzheimer's Disease Brain Supernatants, 240 BIOCHEM. BIOPHYS.
REs. COMMUN. 715 (1997).
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nondirectiveness is appropriate, at least in the situation where the pa-
tient has had the test and received a positive result. In such a case,
observing the norm of nondirectiveness is easy, indeed virtually
costless, because there is no treatment to refrain from recom-
mending, and, therefore, no temptation to "impose one's values" by
urging the patient to undergo a therapy one believes she should have.
The situation is quite different if there is an effective treatment
for a potentially lethal disease that can be detected by a genetic test.
In this case, the clinician will reasonably believe that there is a single
right course of action, and that the ethical responsibilities of the pa-
tient are clear from the perspective of widely accepted and easily de-
fended values.
At present there are few such conditions. Perhaps the clearest
case of a lethal late-onset disease that meets this description is heredi-
tary hemochromatosis. 4 If detected early enough, hereditary
hemochromatosis has a simple, inexpensive, virtually riskless, and fully
effective treatment;15 yet this disease has devastating effects on the
liver, heart, and endocrine system if left untreated.' 6 Genetically-
based colon cancer is another example of a late-onset disease for
which there is a genetic test and which can be successfully treated.
However, the success rate for colon cancer treatment is lower and the
treatment more invasive than that for hereditary hemochromatosis. 17
It is reasonable to expect that in the future there will be more cases
where those who test positive for a serious genetic condition will have
the option of a successful treatment. For example, this is likely to be
the case with at least some genetically-based cancers, once the role of
the relevant genes in the development of the diseases is better
understood.
The case of hereditary hemochromatosis, though at this time un-
usual so far as the efficacy of treatment goes, illustrates the danger of
generalizing ethical assumptions that may make sense for diseases for
which the prognosis is much bleaker. In the case of this relatively
common genetic disease, a policy of nondirectiveness is much more
dubious than in the case of reproductive-predictive tests or diagnostic-
predictive tests for lethal, untreatable disorders such as Huntington's
14. See supra note 3.
15. The Treatment is "dce-ironing" (removal of excess stored iron) by phlebotomies
(removal of blood). See David L. Witte et al., Hereditary Hemochromatosis, 245 CLINIcA CHIM-
ICA ACTA 139, 143 (1996).
16. See id. at 139.
17. See Ian Tomlinson et al., Molecular and Cellular Biology of Prostate Cancer, 16 CANCER
& METASTASIS REVIEWS 67-68 (1997).
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disease, and it is much more difficult to dismiss the notion that pa-
tients have a responsibility to inform relatives that they are at risk.
Moreover, when exploring the ethical responsibilities of clinicians" it
will become clear that the more a genetic disorder resembles the
favorable case of hereditary hemochromatosis, the stronger the case is
for clinicians to be "directive" by urging patients at risk to take the
genetic test and for informing the patient who tests positive that he or
she should tell relatives that they are at risk.
The fundamental point here is that it is necessary to think in
terms of a continuum of tests for genetic disorders, with hereditary
hemochromatosis at one end of the spectrum and Huntington's dis-
ease and Alzheimer's disease at the opposite extreme. On the left end
of this spectrum, we have a disease that is cheaply, safely, and effec-
tively treatable; on the right, we have those for which there presently is
no effective treatment. Between the extremes we can locate the
BRCA1 and BRCA2 gene tests (at present closer to the right end of
the spectrum) and the test for the colon cancer susceptibility gene
(closer to the left end). Depending upon where a test lies on the
spectrum, different ethical judgments about the responsibilities of pa-
tients and clinical geneticists will apply.
5. The Likelihood of Ethically Significant Changes in the Institutional
Framework of Genetic Testing
Fifth and finally, how we have come to think about the ethical
responsibilities of patients and clinicians regarding genetic tests has
also been shaped by features of the institutional framework within
which decisions concerning testing have arisen. When assumptions
about the institutional framework are treated as if they were perma-
nent features of the ethical landscape, they become unquestioned
framing assumptions for our thinking about ethical responsibilities.
Although we tend to take their permanence for granted, they can
change and, in some cases, already are changing.
There are two basic institutional facts that have framed our think-
ing about the ethics of telling and testing: (1) a positive test for a
genetic condition carries the risk of insurance discrimination, 19 and
(2) genetic testing is a relatively rare event, not an integral element of
18. See infra text Section IV.
19. See Billings et al., supra note 2, at 481 (concluding that many health care institu-
tions erroneously perceive genetic conditions as "extremely serious," "disabling," or "le-
thal," and as a result of this misconception, insurance institutions and employers use
genetic testing information inappropriately by restricting or limiting access to public enti-
tlements such as health care or employment).
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routine health care, and physicians play a pivotal role in broaching
the issue of whether to have a genetic test and how to respond to the
results.
The actual extent of insurance discrimination on genetic grounds
is disputable. It is quite possible that anecdotal evidence of discrimi-
nation overestimates the frequency with which individuals are denied
insurance because they are known to have a genetic condition.20
More importantly, the risk exists only for insurance policies whose is-
suance is conditional on medical underwriting, and most Americans
who have private insurance get it through large group policies in
which there is no medical underwriting.2 Nevertheless, the public
perception seems to be that insurance discrimination on genetic
grounds is or, with the emergence of more genetic tests, will become,
a major problem.22 This perception, whether accurate or not, has led
to a flurry of legislative initiatives, at the state and federal levels, that
may in time succeed in prohibiting insurance discrimination on ge-
netic grounds.
2 3
Whether we assume that there is a risk of insurance discrimina-
tion, and how serious we assume that risk to be, makes a difference
when determining the ethical responsibilities of both patients and
physicians. For this reason it is important to note that this first institu-
tional fact may change, and to explore the difference this would make
in how we should understand the ethical responsibilities of clinicians
and patients (as well as individuals who may not be the patient of any
physician). The change could occur either through legislation
prohibiting refusal to insure on genetic grounds24 or, less probably,
through the replacement of the competitive private health care insur-
ance market with a universal coverage, single-payer system.
The second institutional fact has two parts: (1) the relatively small
role that genetic testing plays in health care at this time (especially
outside the reproductive-choice context) and (2) the fact that when
genetic testing does occur the physician controls access to these tests.
20. See id. at 477.
21. See Joel Cantor et al., Private Employment-Based Health Insurance in Ten States, 14
HEALTH AFFAIRS 199, 205 (1995).
22. See Karen H. Rothenberg, Genetic Information and Health Insurance: State Legislative
Approaches, 23J.L. MED. & ETHICs 312 (1995).
23. See Rothenberg, supra note 22, at 313-17; see, e.g., H.R. 306, 105th Cong. (1997)
(prohibiting discrimination against individuals and their family members on the basis of
genetic information, or a request for services); H.R. 328, 105th Cong. (1997); S. 89, 105th
Cong. (1997); S. 1600, 104th Cong. (1996)); S. 1416, 104th Cong. (1995); H.R. 2690, 104th
Cong. (1995);
24. See Rothenberg, supra note 22 and accompanying text.
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This second feature is already changing. As noted earlier, companies
in the United States and the United Kingdom are already "direct mar-
keting" home genetic test kits25 which require no role for a physician.
There is every reason to believe that this trend will grow with the ex-
panding repertoire of genetic tests.
It is difficult at present to know whether, or when, the use of diag-
nostic-predictive genetic tests will become pervasive in the United
States' health care market. Much will depend upon whether the cur-
rent trend toward managed care continues (which seems likely) and
on the willingness of managed care organizations to include genetic
tests among the services they cover. 6 If inexpensive, "one-shot" blood
or cheek cell sample genetic tests that detect dozens of genetic condi-
tions at a time become available, and if the problem of insurance dis-
crimination is solved, genetic testing may become a routine part of
health care. If genetic testing does become a routine part of health
care, it will no longer be the case that unless individuals who tests
positive for a genetic condition inform relatives of the results of their
tests, they will be unlikely to know that they are at risk. This point is
worth reflecting upon, because it is usually assumed that the "age of
genetic medicine" will be one in which the crucial and recurrent issue
for patients who test positive will be: What are my obligations, if any,
to inform relatives at risk? If everyone is getting a standard battery of
genetic tests, this question will lose much of its urgency.
The time is ripe, then, for a critical investigation of the ethics of
genetic "testing and telling" for patients and physicians. In particular,
it is important to avoid begging important questions by assuming that
all genetic tests or even all genetic tests of a general type, such as
diagnostic-predictive tests, are alike from an ethical point of view.
Likewise, we must be careful to understand the role which institu-
tional framework assumptions are playing in our beliefs about 'vhat
our ethical responsibilities are.
To correct what I take to be the distorting focus on reproductive-
predictive tests, I will concentrate on diagnostic-predictive tests, but
much of what I say will apply to reproductive-predictive tests as well.
At relevant points in the investigation, I will ask how changing our
25. See SCIENCE AND TECHNOLOGY COMMI-rEE, supra note 6 and accompanying text.
26. Until recently it was assumed that health maintenance organizations (HMOs)
would encourage preventive care. If this assumption holds, then one might predict that
HMOs would be quick to utilize at least those diagnostic-predictive genetic tests that detect
diseases that are responsive to therapies or life-style changes. But if enrollments are unsta-
ble - if individuals shift from one plan to another over time - the incentive for preven-
tion is diminished.
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assumptions about institutional arrangements affects ethical
conclusions.
III. PATIENTS' ETHICAL RESPONSIBILITIES
There are two decision points at which the question of ethical
responsibilities for patients arises: (1) deciding whether to have a ge-
netic test (or whether to inquire about having one) and (2) deciding
what to do in response to receiving the results of the test.27
This section will concentrate on the latter, but much of what is
written will have evident parallels for the former. The subject of this
inquiry is even narrower. That is, what ethical responsibilities to "tell"
- to inform others of the positive results of the test - might the
patient have and to whom?
For example, John has just received a positive result for a diagnos-
tic-predictive genetic test. Does John have a responsibility to inform
relatives that they are at risk for the condition? If so, which relatives
(e.g., second and third cousins, orjust first cousins, or only relatives of
the first degree) and what constitutes fulfillment of this responsibility (e.g.,
how much time and effort must he expend to contact the required
relatives he should contact and to explain the significance of the test
in terms they can understand)?
To answer these questions two things are necessary. First, we
must clarify the possible sources of duties to tell, the moral considera-
tions that support the assertion that there is a duty; second, we must
articulate the factors that determine the scope and weight of whatever
duties there are and see whether, or to what extent, these factors are
present in various types of test situations, that is, for tests for various
types of conditions.
A. Possible Sources of Duties to Tell: General and Special Obligations to
Prevent Harm
Virtually all known ethical views, whether ancient or modern, reli-
gious or secular, recognize a general obligation not to cause harm to
innocent persons. Most also recognize a general obligation to prevent
harm as well, at least if the harm is serious, even if this is understood
to be a more circumscribed obligation than the obligation not to
cause harm. Thus for example, one might be morally required to risk
27. For brevity I will continue to use the term "patient" to distinguish these individuals
from physicians, while acknowledging that the prospect of home-test kits means that indi-
viduals can be tested without being patients.
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one's life to save an innocent person one has caused to be in peril, but
not to save someone for whose endangerment one did not cause.
To say that an obligation is general is to say that it applies to all
individuals, not simply those who stand in certain special relationships
to one another (e.g., parent-child, physician-patient). General ethical
obligations are those that are thought to provide the basic moral
framework for interactions among persons.
To say that there is a general obligation to prevent harm, and not
merely avoid causing harm, is not to deny, of course, that the distinc-
tion between causing harm and not preventing harm is morally signifi-
cant in many contexts. More blame may attach to causing harm, and
the costs an agent is expected to bear in order to avoid causing harm
may be greater than those for preventing harm that one does not
cause. However, the same basic concern for human well-being that
ultimately grounds the obligation not to cause harm, grounds at least
a presumption that one ought to prevent harm to persons as well.
Generally speaking, whether an individual may bear some responsibil-
ity for a harm depends upon whether he was in a position of control,
that is, whether he had the ability to prevent the harm, not whether
he caused the harm. There are a number of reasons for believing that
the obligation to prevent harm is far from an unconditional one. The
most important, perhaps, is that if persons were expected to prevent
all the harms they were capable of preventing they would have few
resources and energy left for their own projects and for showing spe-
cial regard for those with whom they are intimately connected, such as
members of their own families. An open-ended obligation to prevent
harm would be absurdly onerous; it would make us slaves to the risky
behavior of others. Therefore, the scope of the obligation to prevent
harm, whatever its weight vis-ti-vis other obligations with which it may
conflict on occasion, must be understood as being limited by a "rea-
sonable cost" clause. The costs one ought to bear in order to prevent
harm one does not cause are generally lower than those one ought to
bear to avoid causing harm.
Other things being equal, what constitutes reasonable costs de-
pends, in part, upon the seriousness of the harm to be prevented.
Thus, although I may not be obligated to risk my life to rescue a stran-
ger from a burning building (at least if the risk is great), I may be
morally required to miss an important appointment to save an inno-
cent life (but not to prevent a stranger from suffering a very minor
and transient harm). We can summarize by saying that the general
obligation to prevent harm is limited to efforts that incur reasonable
JOURNAL OF HEALTH CARE LAW & POLICY
costs and that what constitutes reasonable costs is determined, in part,
by a principle of proportionality.
Individuals have special as well as general obligations to prevent
harm. Special obligations arise from promises, contracts, and certain
relationships. The special obligations to prevent harm among family
members may be more weighty than general obligations. This is par-
ticularly evident in the case of parents' obligations toward their minor
children because it is parents' choices that result in children being
brought into the world in a condition of dependency and
vulnerability.
Similarly, the duty to prevent harm to one's spouse is generally an
especially weighty one because marriage vows pledge mutual support
and unique loyalties. Whether an individual has especially weighty ob-
ligations to prevent harm to siblings, simply because they are siblings,
is less evident. For in this case there is no element of choice as there
is in the case of children or spouses.
To extend the "higher cost" principle beyond the relationship be-
tween parents and children and between spouses to biological rela-
tionships generally is more problematic. The standpoint of our
responsibilities to prevent harm is not whether someone is biologically
related, or how close the biological tie is, but the character of the
interactions with that individual - the legitimate expectations and
patterns of reliance, and the debts of gratitude that have arisen from
the interactions. Thus, acting ethically may require that I bear a
greater cost to prevent harm to my friend, to whom I have no biologi-
cal tie, than to my brother, from whom I have been separated since
early childhood.
In some cultures, relationships among relatives beyond the nu-
clear family are closer than in other cultures. Members of the ex-
tended family are connected by a dense web of on-going cooperative
interactions. These patterns of cooperation can generate special obli-
gations that would not otherwise exist, and they can add weight to the
special obligations that typically exist in all families. The special obli-
gations characteristic of close extended families have their source
both in the need to avoid thwarting the legitimate expectations of mu-
tual aid which these on-going patterns of cooperation generate and in
what is sometimes called justice as reciprocity, according to which
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those who accept the benefits of a cooperative enterprise are obli-
gated to do their fair share in sustaining it.
28
The extent and robustness of special obligations within families
vary not only across cultures, but within cultures. In some families, for
an individual to fail to inform the members of his extended family
that he has tested positive for a serious but effectively treatable genetic
disorder might be acceptable; in others, not informing them would be
inconsistent with legitimate expectations of mutual protection. This
makes it even more difficult to make sound generalizations about the
extent and weight of an individual's obligation to tell others of the
results of a genetic test.
Considering the distinction between general and special obliga-
tions to prevent harm, as well as the "reasonable costs" limitation and
the proportionality constraint on the latter, how does this all apply to
the case of "telling" the results of a positive genetic test? Under what
circumstances, if any, does a person who has just learned that he has
tested positive for a deleterious genetic condition have an ethical obli-
gation to inform biological relations that they are at risk?
Consider a case where John tests positive for the C282Y muta-
tion 29 for hereditary hemochromatosis. He knows that he has two
copies of the mutation which accounts for the majority of cases of
non-acquired iron overload disease. He knows that the disorder is au-
tosomal recessive and understands that this means that his siblings
each have a one in four chance of having two copies of the mutation.
Assume that he also knows that those who have two copies have a high
probability of serious damage if not diagnosed and treated before
stored iron levels reach toxic levels. To simplify the case further, as-
sume that the siblings are both males.3 ° Recall that the treatment for
this condition, regular phlebotomies to reduce iron levels, is safe, rela-
tively noninvasive, cheap, and fully effective if undertaken early
enough. Finally, because genetic as well as metabolic testing for this
disease is, at present, not part of standard medical examinations, we
28. For a discussion of how participation in mutually beneficial cooperative schemes
can generate duties of reciprocity according to a principle of fairness, see JOHN RAwLS, A
THEORY OFJUSTICE 111-12 (1971).
29. The C282Y mutation is the allele that accounts for the majority of cases of heredi-
tary hemochromatosis. See Wylie Burke et al., Hereditary Hemochromatosis: Gene Discovery and
Its Implications for Population-Based Screening, 9-10 (March 3, 1997) (reporting consensus of a
panel of experts convened by the Center for Disease Control and Prevention and the Na-
tional Institutes of Health, an unpublished manuscript available from National Center for
Chronic Disease Prevention and Health Promotion).
30. Females have a natural "de-ironing" mechanism, menstruation. See id. at 8. This
may account for the fact that women who have hereditary hemochromatosis tend to have
less severe symptoms than men. See id.
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can assume that there is a high likelihood that unless John notifies his
siblings that they are at risk, they will not be tested. Therefore, if
John's siblings have the disease, it will go undiagnosed until serious
and irreversible damage has occurred."
In such a case, the harm to be prevented is great. Those who are
informed that they are at risk must act to prevent the harm especially
if it is unlikely that the harm will be prevented in any other way. The
regimen of phlebotomies itself generally produces no harms of com-
parable weight to the harm being prevented. At this point, a familiar
distinction between prima facie obligations and general obligations is
clearly relevant. John has a prima facie duty, with no commitment to
excessively onerous requirements, to warn in all cases where there is a
reasonable expectation that serious harm will be prevented. There-
fore, John has a primafacie obligation to inform his siblings that he has
tested positive. Whether he has an obligation, all things considered,
to inform them will depend upon whether informing them would im-
pose "unreasonable" costs on John.
The possible risks to John are highly speculative at best. He may
be stigmatized by other family members for being "genetically defec-
tive." A very small possibility exists that whatever risk of insurance dis-
crimination he may have incurred by having tested positive may be
increased if his siblings are tested and one or more test positive and if,
somehow, a data bank of medical records identifies John as being at
risk because he is related to someone who is known to have tested
positive.
It is worth noting that the evidence concerning insurance dis-
crimination against those diagnosed with hereditary hemochromatosis
is mixed. There are self-reporting cases32 of discrimination.33 How-
ever, there is also anecdotal evidence that some individuals undergo-
ing treatment have succeeded in convincing insurers to overturn
initial decisions to withhold coverage.34 Most importantly, many states
now have laws prohibiting or limiting insurance discrimination on ge-
31. Hereditary hemochromatosis is frequently not diagnosed until damage is irrevers-
ible, and neither the metabolic (serum ferritin or transferrin saturation) test for it or the
newer genetic (polymerase chain reaction) test are at this point widely employed. For a
valuable overview of the epidemiology, diagnosis, and clinical management of hereditary
hemochromatosis, see generally, HEMOCHROMATOSIS (James C. Barton & Corwin Q. Ed-
wards eds. 1988); see also Burke et al., supra note 29, at 5-6.
32. Self-reporting refers to surveys in which individuals are asked whether they believe
they have been subject to genetic discrimination.
33. See Billings et al., supra note 2, at 478.
34. Interview with James C. Barton, Director, Southern Iron Disorders Center, Bir-
mingham, Alabama (Aug. 1997).
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netic grounds.3 5 Furthermore, the Clinton administration has called
for federal legislation that would prohibit exclusion from insurance
on the basis of a positive test for hereditary hemochromatosis or any
other genetic condition. 6
Available data on the frequency of genetic stigmatization and its
psychological effects on those stigmatized is if anything even less satis-
factory than data on genetic discrimination in insurance. It seems rea-
sonable to expect, however, that some genetic conditions are more
apt to stigmatize than others - genetically-based Alzheimer's demen-
tia or genetically-based breast cancer may stigmatize quite differently
than excessive iron storage. Some anecdotal evidence indicates that
hereditary hemochromatosis patients do not tend to experience stig-
matization.3 7 Furthermore, it cannot be assumed that whatever stig-
matization hemochromatosis patients may experience is so serious as
to exceed the "reasonable cost" proviso on the obligation to prevent
harm. A reasonable cost to bear is proportional, within limits, to the
seriousness of the harm to be prevented, and the harm to be pre-
vented in the case of hereditary hemochromatosis is very grave.
There is another possible cost to John. If his relationship with
one or both of his siblings is strained or in conflict, then it may be very
difficult for him to communicate the information effectively.3 8 It is
important to emphasize that John cannot be expected to successfully
convey the information (anymore than a physician can be expected to
successfully make a patient understand the risks of a procedure).
John's obligation is to make a good faith effort to provide his siblings
with information which may enable them to avert a grave harm.
In some cases, discharging this obligation may be relatively easy.
The best way for John to discharge his obligation to inform may sim-
ply be to tell his siblings that he has tested positive which means that
they are at a higher than average risk for the disease. In other cases, if
John has good reason to believe that there is some question as to
whether they would want to be informed, it may be more appropriate
for him to tell them that he has received some information about his
own health status that is relevant to their own and leave it up to them
35. See Rothenberg, supra note 22, at 313-17 (describing fifteen state statutes and the
extent to which discrimination is prohibited).
36. See The White House Briefing Room (visited Jan. 20, 1998) <http://
www.whitehouse.gov/WH/html/briefroom.html>.
37. Interview with Peter Beatty, M.D., Meriter Hospital, Oncology and Hematology De-
partment, Madison, Wisconsin (Feb. 1996); interview with James C. Barton, Director,
Southern Iron Disorders Center, Birmingham, Alabama (Aug. 1997).
38. Personal oral communication with Gail Geller, Associate Professor, Johns Hopkins
Medical Institution and Institute of Biomedical Ethics (Aug. 1995).
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to decide whether to inquire about the specific character of the
information.
Given the facts of the case as described, we may conclude that
John has an obligation to inform his siblings that he has tested posi-
tive, unless he has some special reason, based on his knowledge of his
siblings' preferences, to take a more guarded approach. He has this
obligation regardless of whether he has a "special" relationship with
his siblings (as opposed to his children or spouse). John is in a posi-
tion to prevent serious harm because he is a sibling of the other indi-
viduals. However, he would still be obligated to inform his siblings of
his positive test results if he had been separated from them at birth,
and had no relationship with them but somehow knew how to contact
them with the news of his test. What is crucial for his responsibilities
is the fact that he can act to prevent serious harm which is not likely to
be prevented otherwise and can do so with little cost to himself.
The conclusion thatJohn should inform his siblings of the results
of his test assumes, of course, that they have not instructed him that
they do not wish to be informed and that he has no other good reason
to believe that they do not wish to be informed. The obligation to
prevent harm is limited by respect for the autonomy of competent
individuals. In the case of some genetic tests, such as the test for
Huntington's disease, 9 some people do not wish to be informed that
they are at risk.40 Given the dreadfulness of the condition and its in-
curability, this preference not to be informed of the risk is under-
standable. The importance of not overgeneralizing across ethically
different tests is clear.
Earlier I noted that one ethically relevant institutional fact is the
risk of insurance discrimination and that this fact may change if the
use of genetic information for exclusion is effectively prohibited.4 '
The preceding example includes another institutional fact that shapes
our conclusions about John's responsibilities: The current health
care system is not doing a good job of diagnosing hereditary
hemochromatosis or of making people aware of the need to be
39. Huntington's disease is a "rare hereditary disease characterized by quick involun-
tary movements, speech disturbances and mental deterioration." BENJAMIN F. MILLER &
CLAIRE B. KEANE, ENCYCLOPEDIA & DICTIONARY OF MEDICINE, NURSING, & ALLIED HEALTH
706 (5th ed. 1992). Huntington's disease appears in adults, ages 30 to 45, causes rapid
deterioration, and usually results in total incapacitation or death. See id. at 706-07. No
cure exists and patients usually need to be institutionalized. See id.
40. See Ann-Marie Codori et al., Self-Selection in Predictive Testing for Huntington's Disease,
54 A.M. J. MED. GENETICS 167, 170 (1994).
41. See Billings et al., supra note 2, at 481 and accompanying text.
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tested.4 2 If John's siblings and all other males over the age of forty
were tested routinely for hereditary hemochromatosis as part of a pro-
gram of periodic physical exams made available by a national health
care system, one important fact in our scenario would change: It
would not be the case that the harm John seeks to prevent would
likely occur unless he acts to prevent it.
John's ethical responsibilities seem straightforward: He ought to
inform at least his siblings and to suggest that they inform their chil-
dren, especially if they are male, that they are at much greater than
average risk for liver and heart disease. Matters get more nebulous as
John begins to consider how far his obligation to inform relatives ex-
tends. Should he notify the offspring of his deceased father's de-
ceased brother? If John is homozygous4" for the mutation, then the
probability that everyone in his extended family is at greater risk than
the general population is increased. Does this mean that he has an
obligation to inform all of them? What if doing so involves considera-
ble time and expense?
No determinate answer to these questions exists. The boundaries
of the obligation to prevent harm, whether we consider it a general
obligation or a special one, are not clearly demarcated. However, the
more remote the biological ties, the less likely that the relative will
have the medical condition. In addition, the more remote the rela-
tive, the greater the cost for John to locate and notify those relatives.
In general, as the circle of biological relatives expands, John's obliga-
tions attenuate. It is not possible to locate a precise point at which he
no longer has an obligation to make any effort to inform.
There is another reason to conclude thatJohn is not obligated to
inform the most distant relatives of the results of his test: He may, in
fact, be obligated not to contact them in consideration of their privacy.
The lower the probability that they will be affected, the more the value
of their privacy weighs against informing them.
Nevertheless, a significant obligation exists in some circum-
stances to inform others of the positive results of a genetic test (e.g.,
the hereditary hemochromatosis case described above). The princi-
ple moral obligation to inform others of the results of one's positive
genetic test is the obligation to prevent harm. It is important to deter-
mine whether one actually has an obligation (as opposed to a prima
42. See Burke et al., supra note 29, at 7.
43. In this context, "homozygous" means having two copies of the mutated gene. See
CHURCHILL'S MEDICAL DICTIONARY 289 (2d ed. 1989).
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facie obligation). If an obligation is present, then the extent of the
obligation depends upon the following factors:
1. The severity of the harm to be prevented (the more se-
vere the harm, the weightier the obligation);
2. The probability that the harm will occur if the individual
is not informed (the higher the probability, the weightier
the obligation);
3. Whether there is a "special" relationship between the indi-
vidual who is in a position to inform and the one who
would benefit from being informed (Special obligations
generally are weightier in the sense that they count as
"reasonable" higher costs.);
4. The costs to the individual who will be informed of
preventing the harm (e.g., a, regimen of phlebotomies in
the case of treatment for hereditary hemochromatosis ver-
sus preventive surgery in the case of colorectal cancer or
perhaps preventive mastectomy in the case of BRCA1)
(the lower these costs, the greater the net benefit of being
informed and the weightier the obligation to inform);
and
5. The costs of informing to the informer, including primar-
ily: (i) the risk of insurance or employment discrimina-
tion (the probability that exclusion from coverage or loss
ofjob opportunities will occur times the cost of exclusion
or loss of job opportunities to the individual excluded),
and (ii) the risk of stigma (the probability that the one
who informs others of his positive test will be stigmatized
times the magnitude of the harm to him of being stigma-
tized) (the lower these costs, the stronger the case for say-
ing that there is an obligation to inform).
B. Less Favorable Cases for Attributing an Obligation to Inform Relatives
Consider a quite different situation, at the other end of the spec-
trum of responsibility, where there is no clear obligation to inform
relatives at risk. Suppose that Mary is tested for the APO E4
"Alzheimer's gene" and is told that she is homozygous for it. She is
also told that there is at least a 90 percent probability that she will
have Alzheimer's disease by the age of 65 (and an even higher
probability if there is a significant history of this disease in her family).
Is Mary obligated to tell her relatives of the results of her test?
Assume that the obligation to prevent harm is the most signifi-
cant source of a possible obligation to tell. Since no effective treat-
ment for Alzheimer's is currently available and learning that one is at
much higher than average risk may be very distressing, then the case
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for informing relatives is very weak. Furthermore, the cost to Mary of
informing others is likely to be higher than John's cost of informing
others. The stigma of Alzheimer's may be greater because it is a dis-
ease that destroys the characteristics of persons that we value most. In
addition, the risk of insurance discrimination, especially for long-term
care insurance, may be considerably greater.
This is not to say that there are no benefits of being tested for the
"Alzheimer's gene," nor that there are no benefits that Mary's relatives
might derive from knowing about the positive results of her test.
Some physicians and spokespersons for Alzheimer's organizations
have wrongly assumed that if there is no medical benefit to be derived
from testing (because there is no effective therapy), then there is no
benefit.4 4 This assumption is mistaken for two reasons. First, some
who test for the "Alzheimer's gene" will test negative, and a negative
result may relieve anxiety. Second and perhaps more importantly, for
some individuals, knowing that they have a very high probability of
becoming severely disabled and cognitively impaired at a relatively
early age may be a benefit, despite the psychological distress it causes,
because this knowledge will lead them to plan their lives differently.
For example, if one knows that there is a very high probability that
one will have Alzheimer's by age sixty-five, one may have children at
an earlier age, in order to be able to enjoy more years with them and
with grandchildren, one may choose shorter term investments, retire
earlier, or even choose a different career.
Those who overlook these benefits and focus only on the psycho-
logical costs of a positive test and the fact that there is now no effective
treatment, commit a classic fallacy that is characteristic of medical pa-
ternalist thinking:45 They reduce benefits to medical benefits, or they
wrongly assume that what they themselves would not regard as benefi-
cial cannot be beneficial to the patient.
When Mary contemplates whether to inform her relatives of her
positive test, she cannot assume that simply because there is no effec-
tive treatment, there is no benefit that her relatives could derive from
knowing her test results. Some of her relatives might wish to know,
and if they knew, they might take the test themselves. Nevertheless,
even if Mary would like to know whether she has the gene because she
44. Personal oral communication with Tikka Beard, spokesperson for the Utah
Alzheimer's Organization (Apr. 1996).
45. Here medical paternalist thinking should be understood to mean thinking that
assumes that physicians may interfere with the liberty of action or freedom of information
of competent patients for the patients' own good. See Allen Buchanan, Medical Paternalism,
7 PHIL. & PUB. AFFAiRs 370, 372 (1977).
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wants to be able to plan her life differently if she does, she cannot
assume that others will feel the same way. It is a different matter if she
knows that some particular relative to whom she is very close definitely
would want to know if he is at higher than average risk. She can as-
sume, however, that most people will be distressed to learn that a rela-
tive, especially a close relative, has the "Alzheimer's gene" and that
consequently they are at risk for this terrible, incurable illness. Given
this constellation of factors, it would be implausible to argue that
Mary has an obligation to tell even her close relatives about the results
of her test.
Genetic testing for hereditary hemochromatosis and for APO E4,
or for Huntington's disease lie at the opposite extremes of a spectrum
of responsibility. Other tests, including some that are likely to be-
come available in the next decade, present a much more ambiguous
picture for the ethics of telling and testing. Where the prospects for
effective treatment are not so certain as with hereditary hemochro-
matosis nor so bleak as with Alzheimer's, or where there the risk of
stigma or of insurance or employment discrimination is neither negli-
gible nor great, sorting out whether, or to whom, one has the obliga-
tion to tell may be a very complex matter. Where the balance of
reasons lies in any particular case may also depend upon whether ge-
netic testing has become standard medical practice and upon whether
those who might benefit from being told have access to genetic test-
ing. If the tests in question are part of standard medical practice and
if everyone has access to them, then there may be no duty to warn
relatives at risk because they will have the opportunity to be tested
themselves if they wish.
It is likely in the future that the number of genetic tests for ge-
netic susceptibilities to disease will increase. In many cases there will
be no single, fully effective treatment for the condition. Instead, a
positive test for the susceptibility will alert the patient to prepare a
complex strategy of special medical surveillance for early detection of
symptoms, dietary and life style changes, and possibly pharmaceutical
interventions. In such cases the causal chain between receiving infor-
mation that one is at risk and preventing the harm is more complex.
Some of the crucial links in the chain depend upon choices the pa-
tient makes over time (such as whether to change his or her lifestyle
to reduce risk). For any number of reasons, including disruption of
medical coverage due to unemployment or lack of self-discipline, the
patient may not carry out the needed life style modifications or con-
tinue the medical surveillance. Consequently, a person who has been
diagnosed with a genetic susceptibility for which the reduction of risk
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depends upon this complex array of factors may be much less confi-
dent that harm will be prevented if he informs his relatives at risk of
the results of his test.
IV. CLINICIANS' ETHICAL RESPONSIBILITIES
A. Obligations Regarding the Decision to Test Versus Obligations Once the
Test Results are Available
As more and more genetic tests become available, clinicians will
be faced repeatedly with the question of whether they should recom-
mend a particular test to a particular patient or whether they should
even inform the patient of the existence of the test. Clinicians are
obligated to recommend tests or notify patients of their availability if
doing so is required by sound standards of medical practice.46
Relying upon standards of medical practice to determine the phy-
sician's obligation is not sufficient, however, in an area such as genetic
testing, where no coherent standards of practice exist that are capable
of accommodating the flood of new tests that will become available in
the coming years. When practice standards are unclear or rapidly
changing, clinicians must rely upon their judgment about what would
best serve the patient's interests, within the constraints of respect for
the patient's autonomy and privacy.
In addition, whatever standards of practice eventually evolve are
likely to provide only very general guidance at best because, as our
analysis has already shown, it is difficult to generalize across types of
genetic tests. For the fortunate cases where the probability of serious
pathology and of safe and effective treatment are both high, sound
medical care will require that patients at high risk for the condition be
offered the option of testing. Even in these relatively unproblematic
cases, there will be disputes about what constitutes high risk. In any
system that faces the need to limit medical expenditures, what consti-
tutes high risk must be determined in part by cost, or rather by the
ratio of costs to benefits.
In other cases, where the probability of serious pathology or ef-
fective treatment is lower or subject to greater uncertainty, it will be
much more difficult to forge consensus on a standard of care. It is
important to emphasize, however, that there is nothing here that is
peculiar to genetic testing. Many nongenetic diagnostic tests are char-
46. SeeJohn H. Derrick, Annotation, Medical Malpractice: Liability for Failure of Physicians
to Inform Patient of Alternative Modes of Diagnosis or Treatment, 38 A.L.R.4th 900 (1998).
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acterized by these same complexities and ambiguities. 47 As far as the
clinician's obligations are concerned, the fact that positive genetic
tests only reveal a probability of future illness does not set them apart
from other tests.
B. Old Problems of Paternalism, New Applications
Familiar patterns of medical paternalist thinking can distort the
clinician's judgment about whether to offer a test, whether to comply
with a patient's request for a test, or whether to inform a patient about
the availability of a test. In each of these decisions, clinicians must
avoid the error of reducing patient benefit to medical (i.e., therapeu-
tic) benefit and must fix their attention on what is in the patient's best
interest, not what would be in the clinician's best interest.
In other words, the clinician is obligated to take the competent
patient's view of his own best interests seriously. The clinician must
endeavor to know what the patient's values and wishes are. With one
exception, there is nothing here that is in any way peculiar to deci-
sions concerning genetic tests. The exception is that the process of
informed consent to genetic testing should include the clinician's dis-
closure that there may be a risk of insurance or employment discrimi-
nation. Although this is not a "medical" risk in the same way in which
a bladder infection is a risk of cystoscopy,4" it is nonetheless some-
thing a reasonable decision maker would want to be apprised of.49
Given the fact that many patients may be unaware of the risk of insur-
ance discrimination, the person best placed to inform them is the
physician.
C. Medical Needs Versus Market-Generated Preferences
If profit-seeking marketers of tests are successful in generating
patient demand, clinicians will increasingly see patients who request
particular tests or who at least are the first to raise the question of
whether they should be tested. Again, this is nothing peculiar to ge-
netic testing. For many years physicians have been faced with patients
who request or demand antibiotics for the treatment of the common
47. This is evidenced by the common practice of gaining a second opinion from a
specialist.
48. Cystoscopy is a "visual examination of the interior of the urinary bladder by means
of a cystoscope." MELLONI'S ILLUSTRATED MEDICAL DICrIONARY 120 (2d ed. 1985).
49. "A risk is thus material when a reasonable person, in what the physician knows or
should know to be the patient's position, would be likely to attach significance to the risk
or cluster of risks in deciding whether or not to forego the proposed therapy." Canterbury
v. Spence, 464 F.2d 772, 787 (D.C. Cir. 1972).
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cold, even though the treatment is inefficacious. More recently, phar-
maceutical companies, in magazine and television advertisements,
have been appealing directly to individuals to "ask your doctor
about _. " " The advertisements for mail-in hemochromatosis tests
noted above5" are directed not primarily at physicians, but at consum-
ers. The fact that these issues are familiar in nongenetic contexts does
not make it easier to determine the clinician's obligations. Clinicians
must steer a course between reverting to the paternalism of an earlier
era and becoming passive vendors of services who respond unques-
tionably to patient demands, or even worse, becoming marketers who
stimulate consumer demand for the sake of profit, and thereby for-
sake the notion of medical need.
To revert to paternalism is to fail to take the competent patient
seriously as a partner in decision making and as a person whose own
estimate of his best interests ought to be honored. Simply to respond
to patient demand, no matter how misguided, or to ignore the distinc-
tion between preference and medical need, is to abdicate professional
responsibility by refusing to exercise professional judgment.
D. The Clinician's Obligations After the Patient Tests Positive
I will assume what I hope is, at this stage in the development of
medical ethics, uncontroversial: If a competent patient tests positive,
then he or she is to be informed. Instead of re-enacting familiar bat-
tles against medical paternalist justifications for not informing pa-
tients of test results, I wish to focus on what the responsibilities of the
clinician are after the disclosure of a positive result has been made to
the patient.
The most obvious questions are these: (1) Should the clinician
advise or urge the patient to notify relatives at risk? (2) If the patient
refuses to do so, should the clinician notify them?
E. Nondirectiveness, an Outmoded Norm?
Answering the first question requires a critical assessment of the
norm of nondirectiveness. This norm - which has achieved the sta-
tus of a dogma - was developed in the peculiar context of reproduc-
tive-predictive testing.52
50. See, e.g., Advertisement, Depression saddens. Prozac can help. HEALTH, Nov,/Dec.
1997, at 20-22; Advertisement, Zocor, HEALTH, Nov./Dec. 1997, at 27-28.
51. See supra text Section II.A.
52. See Geller et al., supra note 7, at 1120 and accompanying text.
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It is important to understand that the norm of nondirectiveness is
not a fundamental principle of morality, nor is it a norm that is gener-
ally followed or thought to be appropriate in any other area of medi-
cal practice. In most cases, patients expect their physicians to
recommend a course of action in response to a positive test. For ex-
ample, if a patient is told that she has cancer, she will generally expect
that the physician will suggest a course of treatment.
The norm of nondirectiveness is the product of a certain histori-
cal experience. Earlier we sketched the broad outlines of its origins.5"
Nondirectiveness was nourished by the peculiar context of reproduc-
tive decision making, in the midst of the controversy over abortion,
and in an effort to dissociate modern genetics from the taint of eugen-
ics.54 Once one leaves the context of reproductive-predictive testing,
it is much less plausible to advocate nondirectiveness - unless one
thinks that physicians should be more concerned about avoiding any
hint of an association with eugenics than about helping patients un-
derstand that they, like other human beings, have ethical obligations.
Applied to the situation of a positive diagnostic-predictive test,
the norm of nondirectiveness imposes limits on what the clinician may
communicate to the patient about the nature of the choices con-
fronting the patient. Here, it is useful to distinguish two different un-
derstandings of nondirectiveness: strong and weak. According to
strong nondirectiveness it would always be wrong for the clinician to
tell the patient that the patient has an obligation to inform even her
closest relatives of her positive genetic test. According to weak
nondirectiveness, it may be appropriate or even obligatory for the cli-
nician to tell the patient that she ought to inform relatives at the high-
est risk (e.g., siblings), but the physician should not go beyond
informing the patient of what the he takes her obligation to be. For
example, pressuring the patient to inform by implicitly threatening to
break off the therapeutic relationship or by threatening to inform the
relatives if she does not, is impermissible according to weak
nondirectiveness.
It is probably fair to say that the orthodox doctrine, at least
among genetic counselors in this country, is that strong nondirective-
ness is the appropriate norm55 (whether those who profess it to be
53. See supra text Section II.
54. See generally, KEVLES supra note 8 and accompanying text.
55. See F.C. Fraser, Genetic Counseling, 26 Am. J. HUM. GENETICS 636 (1974) (discourag-
ing communication of anything but the facts in genetic counseling); M. Yarborough et al.,
The Role of Beneficence in Clinical Genetics: Nondirective Counseling Reconsidered, 10 THEORETI-
CAL MED. 139 (1989) (observing that the dominant view of genetic counseling insists that it
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always comply with it is another matter). The justification for
nondirectiveness is the need to avoid the clinician's "imposing his val-
ues" on the patient. 6 It does not follow, however, that one need to go
as far as strong nondirectiveness to avoid "imposing values."
Generally speaking, it would be hyperbole to say that when one
individual tells another that he should do something, there is an im-
position of values. In fact, there is something odd - indeed some-
thing demeaning and disrespectful - about the assumption that
merely offering such a judgment about a person's obligations shows
disrespect or is an infringement of autonomy. It is to assume that the
patient is a very fragile vessel that will be shattered at the very sound of
normative language.
Depending upon whether it comes from a physician or a layper-
son, the judgment that the patient has an obligation to inform rela-
tives at risk that the patient has a genetic disease may have quite
different effects. Because of what might be called "status-deference"
toward physicians, the physician risks imposing her values if she sim-
ply states that the patient has an obligation to inform her relatives."
It is true that in the United States until very recently, physicians
qua physicians have been treated as figures of considerable authority.
However, many patients have begun to take a more critical attitude
toward their physician's statements and recommendations."8 With
some patients, status-deference may increase the risk that a patient
will feel pressured into doing what the physician states that the pa-
tients should do. Nevertheless, a physician may reduce this risk by
being careful to make it clear that the patient will not be penalized if
he chooses to ignore the physician's view about what his responsibili-
ties are. To the extent that status-deference toward physicians varies
across cultures, the risk that by informing patients of their ethical re-
sponsibilities to others, physicians will be imposing their values is cul-
turally-variable as well; the higher the status-deference accorded to
clinicians, the higher the risk of clinicians imposing their values.
The primary point is that where the prevention of a serious harm
is at stake, one should not assume that clinicians must abstain from
communicating to the patient any ethical judgment whatsoever, as if
be done "in a nondirective manner wherein the counselor maintains a morally neutral
attitude ...").
56. See supra text Section II.
57. What I call status-deference is to be contrasted with what might be called merit-
deference. Status-deference is deference to a physician simply because he or she is a physi-
cian. Merit-deference is deference based on a perception of the actual abilities of the
individual in question.
58. See PAUL STARR, THE SOCIAL TRANSFORMATION OF AMERICAN MEDICINE 17-18 (1982).
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reducing the risk of imposing values to zero was the only ethical con-
sideration. Infringing the patient's autonomy by imposing one's val-
ues on him is something to be avoided, but it is not to be avoided at all
costs. Furthermore, it is worth noting that there is a clear sense in
which appealing to the patient's moral sensibility, by pointing out
what his obligations are, is a recognition of his autonomy, not a denial
of it. As Kant observed, moral imperatives are directed toward moral
agents, beings who have a will that can enable them to act contrary to
their inclinations. 9 Finally, and most importantly, much will depend
upon how the physician communicates to the patient his belief that
the patient has a moral obligation to notify relatives of the test result.
There is a great difference between asking questions that stimulate
the patient to arrive at the conclusion that she has an ethical obliga-
tion, or if this fails, stating in a calm fashion that one believes that she
does have an obligation, and subjecting the patient to a moralizing
harangue that borders on intimidation or that impugns her character.
The case of John, who tested positive for hereditary hemochro-
matosis, provides the clearest instance of a situation in which the ad-
herence to strong nondirectiveness is not morally defensible.
Suppose, that after explaining the significance of a positive result to
John, John's physician asks him if he has any children or siblings.
John says that he has two male siblings and a male child. The physi-
cian then tells John that there is an issue of ethical responsibility to be
considered. John does not respond to this invitation to consider what
his responsibilities are. Surely the physician should suggest to John
that he should inform his siblings and son that they are at unusually
high risk for a disease that is lethal if not treated. The physician
should suggest to John that he should disclose his test results espe-
cially since there is a safe and effective treatment, and because, at
present, many cases of this disease go undiagnosed until serious, irre-
versible damage has been done.
As suggested earlier, there is another way one can argue against
strong nondirectiveness. One might try to marshall survey data to at-
tempt to show that, in fact, most patients expect their physicians to
exceed the strictures of strong nondirectiveness. They expect and de-
sire their physician to be a moral counselor while showing respect and
not exerting coercive pressure. There is, however, an independent
case for abandoning the nondirectiveness norm: There are instances
in which a patient's ethical obligation to inform relatives is clear and
59. See Immanuel Kant, Groundwork of the Metaphysic of Morals 62-64 (H.J. Paton
trans. 1948) (1792).
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uncontroverted, in the light of the widely accepted principle that we
ought to prevent serious harm. Informing the patient that this is so
need not involve "imposing values."
In some instances, as is presently the case with the tests for Hunt-
ington's, Alzheimer's, or BRCA1 or BRCA2, there will be no clear obli-
gation to inform, and it would be presumptuous and unwarranted for
the clinician to tell the patient that he should inform anyone of the
results of his test. In rejecting strong nondirectiveness, I am not say-
ing that in every case, or even in most cases, the clinician ought to tell
the patient what his obligations are, much less that the clinician
should try to impose a sense of duty on the patient.
Everything will depend upon the particular constellation of the
factors noted above. Instances in which the strongest case can be
made for attributing an obligation to the patient to inform others at
risk will, in general, be those in which it will also be appropriate for
the clinician to tell the patient that he does have such an obligation.
So far, I have argued against strong nondirectiveness. A rejection
of strong nondirectiveness does not entail that the clinician should
inform her patient's relatives that they are at risk if the patient refuses
to do so. John is the physician's patient, not John's relatives. John's
physician has no special obligation to inform John's relatives.6" More-
over, John's physician has a duty of confidentiality with respect to
John, by virtue of his role as John's physician. 6 '
Whether, despite this obligation of confidentiality, it would be
permissible for John's physician to inform John's relatives when John
refuses to do so is a more difficult question. On the one hand, to
inform John's relatives of his test result without his consent would be
to breach the physician's role-specific obligation of confidentiality. On
the other hand, as we have already seen, human beings have general
obligations to prevent harm, and this seems to imply thatJohn's physi-
cian should inform John's relatives, assuming that John refuses to, if
doing so is likely to prevent serious harm.
The strongest argument for saying that it would be impermissible
forJohn's physician to inform John's relatives withoutJohn's consent
60. But seeSaferv. Pack, 677 A.2d 1188 (N.J. Super. Ct. App. Div. 1996) (holding that a
physician has a duty to warn those known to be at risk of avoidable harm from a genetically
transmissible condition).
61. A physician's legal duty to maintain confidentiality arises from licensing statues,
case law, and medical records statues. See, e.g., Humphers v. First Interstate Bank of Ore-
gon, 696 P.2d 527 (Or. 1985); Felis v. Greenberg, 51 Misc.2d 441 (N.Y. Sup. Ct. 1966);
Berry v. Moench, 331 P.2d 814 (Utah 1958). But see, Moses v. McWilliams, 549 A.2d 950
(Pa. Super. Ct. 1988) (holding that a patient's right to confidentiality is not absolute, e.g.,
patient's personal injury action against the doctor).
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is that a proper understanding of the role of physician includes a spe-
cial fiduciary obligation to his patient that extinguishes, or, at least
significantly weakens, what would otherwise be a general obligation to
prevent harm to innocent persons. On this view, the physician's spe-
cial, role-specific obligation of confidentiality toward his patient out-
weighs his general obligation to prevent harm to others.
Even if it is generally true that the role-specific obligation of con-
fidentiality takes precedence over the general obligation to prevent
harm to third parties, it would be implausible to hold that this, or any
role-specific obligation is absolute. The role-specific obligations of
physicians are elements of a particular social practice. The ethical jus-
tification for a particular role-specific obligation, such as the physi-
cian's obligation to preserve confidentiality regarding medical
information about his patient, is justified ultimately by demonstrating
that the social practice in which that obligation is an element pro-
motes human welfare and freedom and does so without unacceptable
infringements of important rights.
Yet one may acknowledge the ethical value of a social practice in
which physicians generally give precedence to special obligations of
confidentiality toward their patients and still concede that there can
be individual cases in which the physician's acting so as to prevent
harm to third parties would be morally preferable. In the well-known
Tarasoff 2 case, legal recognition was given to this belief that role-spe-
cific obligations of confidentiality are not absolute - they can be
overridden in the name of preventing grave harm to a third party. 63 It
is one thing to say that one can describe situations that constitute le-
gitimate exceptions to a generally appropriate role-specific rule of giv-
ing precedence to obligations of confidentiality; it is quite another to
assume that those occupying the relevant role (in this case physicians)
can generally be relied upon to judge accurately and impartially
whether the "exception conditions" are satisfied. In some cases, legiti-
mate exceptions to generally acceptable rules can be specified and
built into the rules as exception clauses. In other cases, an exhaustive
specification of exceptions would either be impossible or would un-
dermine the effectiveness of reliance on the rule by making it too
complicated to apply or by providing too many opportunities for error
or abuse in its application. In the latter types of cases, the best is that
the individuals who occupy the relevant roles will steer a course be-
62. Tarasoff v. Regents of the University of California, 551 P.2d 334 (Cal. 1976) (hold-
ing that a psychiatrist had a duty of care to protect the third party against whom his patient
had threatened bodily harm).
63. See id.
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tween slavish adherence to general rules and a hubristic tendency to
over-estimate their own ability to identify appropriate exceptions.
Once again, noting the broad spectrum of genetic testing situa-
tions proves illuminating and cautions against unsatisfying generali-
ties. In circumstances where there is a very high probability that
informing a relative will avert a great harm, where it is very unlikely
that the harm will be averted if the individual is not informed, and
where the risk to the individual whose confidentiality is breached is
small, a physician may be justified in overriding his role-specific obli-
gation of confidentiality. This is only to say that in this exceptional
case, it would be morally permissible for the physician to do so, not
that breaching the confidence would be ethically required.
The only case of which I am aware that may fit this description is
that of hereditary hemochromatosis.6 4 However, reflections on the
ethical essentials in the case of PKU testing may also lend support to
the claim that the physician's obligation of confidentiality is not abso-
lute. In PKU testing, it is the individual infant who is tested for the
disorder.6 5 Moreover, many states perform testing and treatment
without the consent of the infants parent or guardian.6 6 Suppose,
however, that the only way to detect this metabolic disorder in the
child was to test the mother, but that all the other facts were the same
- the disorder has devastating consequences if not treated, the treat-
ment is effective, and if the test is not done, then it is very unlikely that
the harm caused by the disorder will be avoided. If this was the case,
surely one would not regard the mother's right to confidentiality as
absolute. If she refused to authorize transmitting the test results to
the State Department of Public Health or some other agency charged
with seeing that the treatment is undertaken, one would think itjusti-
fiable to inform them anyway.
At present, this is not the way genetic tests work. Tests are either
performed on the individual in whom the disorder may be detected,
and the prospect that harm will be prevented by informing relatives of
the results is uncertain; or the tests are performed on prospective par-
ents to detect risk in offspring, but the only way to prevent the harm is
to prevent the child from being conceived or born. It is conceivable,
however, that this will change. Prenatal genetic tests might be devel-
64. See supra note 4 and accompanying text.
65. PKU (phenylketonuria) is a metabolic disorder that can result in mental retarda-
tion. See DORLAND'S MEDICAL DICTIONARY 1278 (28th ed. 1994). Damage can be avoided
by a special diet.
66. See Ellen Wright Clayton, Screening and Treatment of Newborns, 29 HOUSTON L. REV
85, 98-99 (1992).
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oped which would predict a very high probability of serious but wholly
avoidable harm. If such prenatal tests are developed, it will be very
difficult to defend an absolute prohibition on breaches of physician-
patient confidentiality.
However, it bears emphasis that the situation is entirely different
in most actual cases of genetic testing, at this point in the develop-
ment of the technology. In virtually every existing case, with the possi-
ble exception of testing for hereditary hemochromatosis, overriding
the role-specific obligation of confidentiality would not be justified,
either because the harm to be prevented is not highly probable, or
because those who are vulnerable to it are likely to learn that they are
at risk in some other way, or because there is no way to avoid the harm
even if the person is informed that she is at risk. Accordingly, it would
not be plausible to assert that a clinician ought to (or even may) in-
form the relatives of Mary, who has tested positive for the
"Alzheimer's gene" (or for BRCA1, or BRCA2, or Huntington's) with-
out Mary's consent. Whether Mary herself should inform relatives
that they are at higher than average risk is another matter, and de-
pends upon the factors discussed.67
V. CONCLUSION
This essay has explored the ethical responsibilities of patients and
clinicians regarding disclosure of genetic test results. I have argued
that the obligation to prevent harm grounds ethical responsibilities
for both patients and clinicians. Whether such obligations exist in a
particular case will depend upon a number of factors which may or
may not be present depending upon the particular facts about the
genetic disorder for which one is testing. Once this more particularis-
tic or contextualized approach is taken, it becomes clear that the
traditional norm of nondirectiveness is not appropriate for all genetic
test situations.
67. See supra text Section III.
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